Advertisement
Screener

AKEBIA THERAPEUTICS, INC. (AKBA) Capital Expenditures Incurred but Not yet Paid

1.9 / 5 stars · 34/88 Roast Me

AKEBIA THERAPEUTICS, INC. Capital Expenditures Incurred but Not yet Paid

AKEBIA THERAPEUTICS, INC. (AKBA) reported Capital Expenditures Incurred but Not yet Paid of $128.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.

Financial Statements › Cash Flow › Other Cash Flow Items

us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-08-05

  • 2026-06-30: Capital Expenditures Incurred but Not yet Paid 6 month $128.00K.
  • 2025-06-30: Capital Expenditures Incurred but Not yet Paid 6 month $0.00.
Period endCapital Expenditures Incurred but Not yet Paid 6 month
2026-06-30$128.00K
10-Q · filed 2026-08-05
2025-06-30$0.00
10-Q · filed 2026-08-05

Similar stocks

Stock NameCountryMarket CapPE Ratio
Lyell Immunopharma, Inc. (LYEL)United States$0.248B-1.32
Pyxis Oncology, Inc. (PYXS)United States$0.244B
Greenwich LifeSciences, Inc. (GLSI)United States$0.267B-15.02
Entrada Therapeutics, Inc. (TRDA)United States$0.243B-1.73
Cue Biopharma, Inc. (CUE)United States$0.243B-1.01
MACROGENICS INC (MGNX)United States$0.242B-20.11
Mereo BioPharma Group plc (MREO)$0.269B-9.41
Camp4 Therapeutics Corp (CAMP)United States$0.240B-2.12
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37
SIGA TECHNOLOGIES INC (SIGA)United States$0.234B-93.33